The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11024 malaria professionals are enjoying the free benefits of MalariaWorld today


NOT Open Access | A Novel Antiparasitic Compound Kills Ring-Stage Plasmodium falciparum and Retains Activity Against Artemisinin-Resistant Parasites

March 9, 2020 - 13:41 -- NOT Open Access
Clements RL, Streva V, Dumoulin P, Huang W, Owens E, Raj DK, Burleigh B, Llinás M, Winzeler EA, Zhang Q, Dvorin JD
The Journal of Infectious Diseases, Volume 221, Issue 6, 15 March 2020, Pages 956–962

Spreading antimalarial resistance threatens effective treatment of malaria, an infectious disease caused by Plasmodium parasites. We identified a compound, BCH070, that inhibits asexual growth of multiple antimalarial-resistant strains of Plasmodium falciparum (half maximal inhibitory concentration [IC50] = 1–2 µM), suggesting that BCH070 acts via a novel mechanism of action.

Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay

December 23, 2019 - 15:09 -- Open Access
Annabelle Walz, Didier Leroy, Nicole Andenmatten, Pascal Mäser and Sergio Wittlin
Malaria Journal 2019 18:427, 18 December 2019

Drug efficacy against kelch 13 mutant malaria parasites can be determined in vitro with the ring-stage survival assay (RSA). The conventional assay protocol reflects the exposure profile of dihydroartemisinin.

Subscribe to RSS - ring-stage